Key facts
- It has raised $95.0M; the latest was Later Stage VC ($95.0M) in Mar 2026.
- Notable investors include RA Capital Management, SR One Capital Management, ArrowMark Partners, FirstTracks Ventures, Platanus — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Poplar Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Poplar Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Poplar Therapeutics
Developer of anti-IgE medicines designed to help patients live free of fear caused by allergic diseases. The company offers next-generation antibody engineering and targeted immune modulation approaches, enabling patients with IgE-mediated conditions to experience improved disease control and enhanced quality of life.
- Sector
- Healthcare
- HQ
- Denver, CO, United States
- Founded
- 2020
- Employees
- 8
- Website
- poplartx.com/
- Ownership
- Privately Held (backing)
Poplar Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Poplar Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Poplar Therapeutics in its N-PORT filings yet. We sweep new filings monthly.